Stephane Peluso

Company: Infinity Pharmaceuticals

Job title: Chief Scientific Officer

Seminars:

Development of Eganelisib, a First-in-Class PI3Kgamma Inhibitor for Next Generation Macrophage Reprogramming Cancer Immunotherapy 12:30 pm

• Discovery of Eganelisib and characterization of MOA • Summary of Eganelisib clinical development program with a focus on translational dataRead more

day: Day Two Track B AM